Free Trial
→ Elon’s BIGGEST warning yet? (From Brownstone Research) (Ad)

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ATT
Abattis Bioceuticals
C$0.00
C$0.05
▼
C$0.74
N/AN/A1.42 million shsN/A
Analysts Agree—These Gold Picks Outshine the Rest Cover
Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ATT
Abattis Bioceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ATT
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ATT
Abattis Bioceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ATT
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ATT
Abattis Bioceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ATT
Abattis Bioceuticals
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ATT
Abattis Bioceuticals
N/A

Insider Ownership

CompanyInsider Ownership
ATT
Abattis Bioceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ATT
Abattis Bioceuticals
N/AN/AN/ANot Optionable

Recent News About These Companies

Abattis Bioceuticals Stock Price History
May 27, 2025  |  investing.comhttps://www.investing.com/equities/abattis-bioceuticals-historical-data
Abattis Bioceuticals Corp. (ATTBF)
August 2, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/ATTBF/news/
B.C. investment dealer that oversaw suspicious, 'unprofitable' trades fined $150K
February 14, 2024  |  richmond-news.comR
B.C. investment dealer who oversaw suspicious, 'unprofitable' trades fined $150K
February 13, 2024  |  vancouverisawesome.comV
Minoxidil Price of 85 Brands
August 1, 2023  |  medindia.netM
Abattis Bioceuticals Stock (OTC:ATTBF), Quotes and News Summary
February 23, 2023  |  benzinga.comhttps://www.benzinga.com/quote/ATTBF
Malaysian Bulk Carriers Bhd (MBCB)
July 26, 2022  |  investing.comhttps://www.investing.com/equities/malaysian-bulk-carriers-bhd
Metrc Enters Government Contract With The State Of South Dakota
March 24, 2022  |  benzinga.comhttps://www.benzinga.com/markets/cannabis/22/03/26256990/metrc-enters-government-contract-with-the-state-of-south-dakota
Cann American Cancels Over 3 Million Common Shares
March 5, 2022  |  benzinga.comhttps://www.benzinga.com/markets/cannabis/22/03/25987493/cann-american-cancels-over-3-million-common-shares
Last Prisoner Project Calls For Support Of Rudi Gammo, Imprisoned For Operating A Medical Cannabis Dispensary
September 1, 2021  |  benzinga.comhttps://www.benzinga.com/markets/cannabis/21/08/22722393/last-prisoner-project-calls-for-support-of-rudi-gammo-imprisoned-for-operating-a-medical-cannabi
Hollister Biosciences Stock Down Slightly On $17.6M Q2 2021 Revenue Report, $3.2M Of Adjusted EBITDA
August 27, 2021  |  benzinga.comhttps://www.benzinga.com/markets/cannabis/21/08/22678038/hollister-biosciences-stock-down-slightly-on-17-6m-q2-2021-revenue-report-3-2m-of-adjusted-ebitd

Top Headlines

View All Headlines

Abattis Bioceuticals CNSX:ATT

Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas